Ovulation inhibition with a log-acting injectable. II. The cycling effects of varying progestagen-estrogen combinations.

ABSTRACT

PIP The cycling effects of long-term injectable progestational compounds were studied to determine the most satisfactory dosage level. The compound Deladroxate (Deladroxone and estradiol enanthate) was administered to 38 subjects in the 5 following doses 150 mg Deladroxone with 5 mg, 10 mg, 15 mg estradiol enanthate; and 200 mg Deladroxone with 5 mg or 20 mg estradiol enanthate. The compounds Deladroxate 150-10 and Deladroxate 200-5 showed the most satisfactory cycling and aftereffects. Further study of Deladroxate 150-10 showed mean cycle lengths of 26.2 and 28.3 days in 143 cycles, a 16% deviation of plus or minus 2 days from a pretreatment means, minimal side effects, and ovulatory cycles that returned within 5 to 13 weeks after withdrawal of the drug.^ieng